Pharma

Indian pharmaceutical company Granules has opened a packaging facility in the Virginia State of the US to expand the packaging capacity of essential drugs in the state, thus strengthening the biopharma supply chain. The facility was inaugurated by India's Ambassador to the US Taranjit Singh Sandhu. Granules, which was one of the first Indian pharmaceutical companies that received FDA authorization to export to the United States, has invested more than USD 100 million in the country, said Dr Krishna Prasad Chigurupati, the founder, chairman and managing director of the firm. "We have nearly 200 employees in Virginia with a large majority of them first-generation Indians," he said, adding the company also has a team of 30 scientists for research and development. Granules India Ltd produces some of the most widely used drugs, including Paracetamol, that have been very useful to billions across the world, Chigurupati said. "Happy to see Made in India' medicines value added in the US b

While the risk from USFDA strictures remains, aggressive investors may take limited bets with 5-7-year horizon

The acquisition will complement DRL's US retail prescription pharmaceutical business with limited competition products

Deal will help the firm add to its line-up of cancer treatments

The company is actively recruiting its field force, and aims to have 600-700 medical representatives by the end of 2023

In the Union Budget 2023-24, Finance Minister Nirmala Sitharaman had hinted at fostering a research-driven climate in the pharma sector in India

The US FDA said that using contaminated artificial tears increases risk of eye infections that could result in blindness or death

Enzene said it has built a highly experienced 400-person team under the leadership of Dr. Himanshu Gadgil, CEO at Enzene Biosciences Ltd

The incident has become a case study in how drug companies artificially prop up prices of their best-selling drugs

May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week

The production licence of Noida-based pharmaceutical firm Marion Biotech, allegedly linked with the deaths of children in Uzbekistan, has been suspended while the results of its controversial cough syrup are awaited, an Uttar Pradesh drug official said Thursday. A team of central agencies and the Uttar Pradesh drug department had carried out an inspection at the firm's office here on December 29 and taken six more samples for testing. During the inspection, the company representatives could not produce documents related to the production of 'Dok-1 max' cough syrup, prompting the government to order halting of its production immediately, Gautam Buddh Nagar Drug Inspector Vaibhav Babbar said. "The production licence of the firm remains suspended, as was ordered on December 29. Now the suspension order has been issued in writing to the firm on January 10 and has been acknowledged by the firm," Babbar told PTI. On the status of the test results, the officer said the samples were taken

Indian Pharma company Marion Biotech Pvt Ltd has halted the production of cough syrup following allegations by Uzbekistan that at least 18 children died in the country after consuming the medicine.

High raw material prices to put pressure on margins

To launch open offer for another 26%; plans merger with Cohance

'Suven alone has multiple engines of growth across all segments and a strong pipeline of Phase 3 and late Phase 2 molecules'

The first nine patients that they will inject would be legally blind, as they have to prove safety first

The Madhya Pradesh government is leaving no stone unturned to facilitate investment assistance to various sectors

Street remains bullish on India prospects, regulatory headwinds for Goa site continue

In July, the RBI had unveiled a mechanism to settle international transactions in rupee to promote the growth of global trade, with emphasis on exports from India

There are demands to extend production linked incentive (PLI) scheme to more sectors such as certain electronic components, pharma and medical devices, and discussions are underway in the government on these proposals, a senior government official said. Discussions are also going on to bring PLI scheme for toys, furniture, bicycles and containers. The objective of the scheme is to make domestic manufacturing globally competitive, create global champions in manufacturing, boost exports and create jobs. The government last year rolled out the scheme with an outlay of about Rs 2 lakh crore for as many as 14 sectors, including automobiles and auto components, white goods, textiles, advanced chemistry cell (ACC) and speciality steel. "So, from Rs 1.97 lakh crore, there are savings from some sectors. So against those savings, things are being planned. Proposals are under consideration," the official said. Demand for including sectors like certain electronic components, toys, furniture,